The aim of the study is to confirm the association between hypermobile Ehlers Danlos syndrome (hEDS) and mast cell activation syndrome (MCAS) in patients with digestive disorders managed in allergology departments.
Study Type
OBSERVATIONAL
Enrollment
30
Mast cell activation syndrome will be confirmed if the following three conditions are met (according to Valent et al, 2012) : * At least two clinical signs compatible with MAS before the first consultation (V1) * Improvement of symptoms on antihistamines within 2 months of initiation of treatment * Significant increase in tryptase during crisis Mast cell activation syndrome will be possible if : * At least two clinical signs consistent with MAS before the first consultation (V1) * Improvement of symptoms with antihistamines within 2 months of initiation of treatment * No significant increase in tryptase during crisis In all other cases, mast cell activation syndrome is unlikely.
Saint-Vincent-de-Paul hospital
Lille, Nord, France
RECRUITINGPrevalence of mast cell activation syndrome in patients with hypermobile Ehlers Danlos syndrome with digestive disorders
The presence of mast cell activation syndrome will be described in three modalities : confirmed, possible, and unlikely. Mast cell activation syndrome will be confirmed if the following three conditions are met : * at least two clinical signs compatible with mast cell activation syndrome (MCAS) before the first consultation (V1) * improvement of symptoms with antihistamines within 2 months of initiation of treatment * significant increase in tryptase during crisis Mast cell activation syndrome will be possible if: * at least two clinical signs compatible with MCAS before the first consultation (V1) * improvement of symptoms under antihistamine at 2 months of the introduction of the treatment * no significant increase in tryptase during crisis In all other cases, mast cell activation syndrome is unlikely.
Time frame: 2 months
Frequency of the symptoms after treatment with anti-histamines
Symptoms are those established by Valent et al, 2012. For each clinical sign the patient will rate the frequency of the symptom: more than once a day, once a day, 2 to 6 times a week, once or less a week, never, over the two months prior to visit 1 (V1), and between V1 and the 2-month follow-up visit .
Time frame: 2 months
Medical Outcome Study Short-Form 36 (MOS SF-36 ) survey after antihistamine treatment
MOS SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability
Time frame: 2 months
Frequency of consumption of analgesics
The frequency of consumption of different analgesics will be studied over the two months preceding V1 and between V1 and V2.
Time frame: 2 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Frequency of intolerance according to particular food consumption
For a given food, at V1 and V2, intolerance will be qualified by the presence of digestive disorders following the consumption of the food among : cow's milk, goat's milk, sheep's milk, fresh cheeses, cow's milk cheese or yogurt, goat's milk cheese or yogurt, sheep's milk cheese or yogurt, wheat/gluten, dry sausage, ham, turkey, chicken, pork, beef, raw egg, cooked egg, smoked fish, canned fish fresh fish, shellfish, mollusks, tomatoes, potatoes, spinach, peas, cabbage, lentils, beans, lemons, oranges, strawberries, raspberries, pineapple, mango, apple, pear, nectarine, peach, banana, kiwi, nuts, peanuts, spices, beers, wines, spirits, other.
Time frame: 2 months